SCHEMBL17519197

CCCCCCCNC(=O)C(CCCCNC(=O)COCCOCCOCCO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O)NC(=O)C(CCCCNC(=O)COCCOCCOCCO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O)NC(=O)COCCOCCOCCO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O

nearest known ligand 0.56

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	MAPK1	P28482	1/20	0.56

▸	GLP1R	P43220	8/20	0.48

▸	ESR1	P03372	1/20	0.46

▸	PGR	P06401	1/20	0.46

▸	HTR1A	P08908	1/20	0.46

▸	ADORA3	P0DMS8	1/20	0.46

▸	AR	P10275	1/20	0.46

▸	CHRM1	P11229	1/20	0.46

▸	TBXA2R	P21731	1/20	0.46

▸	PTGS1	P23219	1/20	0.46

▸	ADRA1A	P35348	1/20	0.46

▸	KCNH2	Q12809	1/20	0.46

▸	EPHX2	P34913	1/20	0.42

▸	SELL	P14151	3/20	0.41

▸	SELP	P16109	3/20	0.41

▸	SELE	P16581	3/20	0.41

▸	ALDH1A1	P00352	1/20	0.41

▸	THRB	P10828	1/20	0.41

▸	MEN1	O00255	1/20	0.41

▸	KMT2A	Q03164	1/20	0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL19820023	1.00	MAPK1 (0.56)	MAPK1GLP1RESR1PGRHTR1A
SCHEMBL25775135	1.00	MAPK1 (0.56)	MAPK1GLP1RESR1PGRHTR1A
SCHEMBL15702040	0.97	GLP1R (0.53)	MAPK1GLP1RESR1PGRHTR1A
SCHEMBL17519200	0.97	GLP1R (0.53)	MAPK1GLP1RESR1PGRHTR1A
SCHEMBL15711575	0.97	GLP1R (0.53)	MAPK1GLP1RESR1PGRHTR1A
SCHEMBL19820097	0.96	MAPK1 (0.52)	MAPK1GLP1RESR1PGRHTR1A
SCHEMBL21016684	0.96	MAPK1 (0.52)	MAPK1GLP1RESR1PGRHTR1A
SCHEMBL20286536	0.96	MAPK1 (0.51)	MAPK1GLP1RESR1PGRHTR1A
SCHEMBL19480776	0.96	MAPK1 (0.51)	MAPK1GLP1RESR1PGRHTR1A
SCHEMBL19820096	0.96	MAPK1 (0.51)	MAPK1GLP1RESR1PGRHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20240067965-A1	ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9	CIVI BIOPHARMA INC (US)	2024-02-29	—	—	US	disclosed
US-20170335323-A1	Chiral Library Screen	ROCHE INNOVATION CENTER COPENHAGEN A/S (CH)	2017-11-23	—	—	US	disclosed
US-20170327524-A1	GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE	HOFFMANN-LA ROCHE INC.	2017-11-16	—	—	US	disclosed
WO-2017178656-A1	TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE	ROCHE INNOVATION CENTER COPENHAGEN A/S (DK)	2017-10-19	—	—	WO	disclosed
US-9487783-B2	Targeting microRNAs for metabolic disorders	Regulus Therapeutics Inc. (US)	2016-11-08	—	—	US	disclosed
US-20160046940-A1	TARGETING MICRORNAS FOR METABOLIC DISORDERS	Regulus Therapeutics Inc.	2016-02-18	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20170327524-A1	GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE	FUT6, FUT5, GALNT6	MAPK1 2092/4885GLP1R 2291/4885ESR1 4527/4885
US-20160046940-A1	TARGETING MICRORNAS FOR METABOLIC DISORDERS	SREBF1, GLS2, FABP1	MAPK1 2834/4885GLP1R 318/4885ESR1 3101/4885
US-20240067965-A1	ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9	PCSK9, SCD5, PCSK7	MAPK1 4221/4885GLP1R 398/4885ESR1 4150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.